A phase 2 trial presented at the American Diabetes Association's conference evaluated maridebart cafraglutide for weight loss in 592 adults, including those with obesity and type 2 diabetes. The long-acting peptide–antibody conjugate showed 12.3% to 16.2% weight loss compared to 2.5% with placebo after 52 weeks. Glycemic improvements were noted in participants with diabetes, while adverse effects were mostly mild to moderate. With a half-life of about 21 days, the drug may allow for less frequent dosing, marking it as a promising option for weight management.

Source: The New England Journal of Medicine